Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic-Reference-Cited by-同舟云学术

Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic

Published:2020-08 Issue: Volume:43 Page:102222
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Ghajarzadeh Mahsa^ORCID,Mirmosayyeb Omid^ORCID,Barzegar Mahdi,Nehzat Nasim,Vaheb Saeed,Shaygannejad Vahid^ORCID,Maghzi Amir-Hadi^ORCID

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference10 articles.

1. Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19;Giovannoni;Mult. Scler. Relat. Disord.,2020

2. Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain;Montero-Escribano;Mult. Scler. Relat. Disord.,2020

3. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran;Safavi;Mult. Scler. Relat. Disord.,2020

4. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?;Novi;Mult. Scler. Relat. Disord.,2020

5. Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab;Suwanwongse;Mult. Scler. Relat. Disord.,2020

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune responses following COVID-19 infection in multiple sclerosis patients using immunomodulatory therapy;Acta Neurologica Belgica;2022-11-04

2. The Outcome of COVID-19 in Patients with a History of Taking Rituximab: A Narrative Review;IRAN J MED SCI;2021

3. COVID-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study;Multiple Sclerosis and Related Disorders;2021-10

4. The Immunological Therapeutic Strategies for Controlling Multiple Sclerosis: Considerations during the COVID-19 Pandemic;Biomolecules;2021-09-17

5. A New England COVID-19 Registry of Patients With CNS Demyelinating Disease;Neurology - Neuroimmunology Neuroinflammation;2021-08-02